New drug: BT-061 for monoclonal antibodies

Approval by regulatory authority to begin clinical development with BT-061. Impressive efficacy of BT-062 in several animal models for Multiple Myeloma. By combining BT-062 with ImmunoGen's proprietary maytansinoid-based TAP technology, Biotest develops a tumor specific antibody-directed therapeutic agent for the treatment of multiple myeloma. BT-062 displays a mode of action that is different from classical chemotherapies. In several preclinical experiments, malignant myeloma cells were destroyed with high effectiveness.

http://www.biotest.de